Iradimed (IRMD) financial statements
Iradimed reported revenue of $84M in fiscal 2025, up 11.1% a year over 9 years.
Net income was $22M and the operating margin 31.2%, against 33.6% in 2016.
Free cash flow was $17M, and the company returned $15M in dividends.
The diluted share count rose 7% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Iradimed's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32M | $23M | $30M | $39M | $32M | $42M | $53M | $66M | $73M | $84M |
| Cost of revenue | $6M | $6M | $7M | $9M | $8M | $10M | $12M | $15M | $17M | $19M |
| Gross profit | $26M | $18M | $23M | $30M | $24M | $32M | $41M | $50M | $56M | $64M |
| Research and development | $1M | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $3M |
| Selling, general and admin | $14M | $15M | $16M | $20M | $22M | $20M | $23M | $27M | $32M | $35M |
| Operating income | $11M | $1M | $6M | $9M | -$756,091 | $10M | $16M | $20M | $22M | $26M |
| Pre-tax income | $11M | $1M | $6M | $9M | -$616,878 | $10M | $16M | $22M | $24M | $28M |
| Income tax | $4M | $896,622 | -$106,143 | -$587,642 | -$2M | $510,816 | $3M | $5M | $5M | $6M |
| Net income | $7M | $499,764 | $6M | $10M | $1M | $9M | $13M | $17M | $19M | $22M |
| EPS (diluted) | $0.60 | $0.04 | $0.52 | $0.78 | $0.11 | $0.74 | $1.02 | $1.35 | $1.50 | $1.75 |
| Diluted shares | 12M | 12M | 12M | 12M | 12M | 13M | 13M | 13M | 13M | 13M |
| Gross margin | 81.1% | 75.9% | 76.3% | 77.1% | 74.3% | 76.6% | 77.4% | 76.5% | 76.9% | 76.7% |
| Operating margin | 33.6% | 5.6% | 19.7% | 22.5% | -2.4% | 23.5% | 29.3% | 30.6% | 30.0% | 31.2% |
| Net margin | 22.2% | 2.2% | 20.7% | 25.0% | 4.3% | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% |
Balance sheet
Fiscal years, from Iradimed's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $26M | $26M | $28M | $43M | $50M | $62M | $58M | $50M | $52M | $51M |
| Receivables | $4M | $4M | $4M | $7M | $5M | $5M | $13M | $12M | $11M | $14M |
| Inventory | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $13M | $10M | $12M |
| Total current assets | $34M | $35M | $45M | $59M | $64M | $76M | $77M | $76M | $75M | $81M |
| Property, plant and equipment | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $9M | $17M | $24M |
| Total assets | $37M | $39M | $48M | $67M | $71M | $83M | $86M | $92M | $98M | $109M |
| Total current liabilities | $4M | $4M | $5M | $6M | $5M | $7M | $9M | $16M | $9M | $10M |
| Total liabilities | $5M | $6M | $6M | $11M | $10M | $11M | $12M | $21M | $12M | $14M |
| Shareholders' equity | $32M | $33M | $42M | $56M | $61M | $72M | $74M | $71M | $87M | $95M |
| Net debt | -$18M | -$18M | -$28M | -$43M | -$50M | -$62M | -$58M | -$50M | -$52M | -$51M |
Cash flow
Fiscal years, from Iradimed's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9M | $3M | $7M | $10M | $6M | $11M | $10M | $13M | $26M | $25M |
| Capital spending | $780,809 | $775,574 | $228,315 | $368,281 | $443,003 | $482,325 | $823,019 | $7M | $8M | $8M |
| Free cash flow | $9M | $3M | $7M | $10M | $5M | $11M | $9M | $6M | $18M | $17M |
| Stock-based compensation | $2M | $2M | $2M | $2M | $4M | $1M | $1M | $2M | $3M | $3M |
| Dividends paid | — | — | — | — | — | — | $13M | $13M | $14M | $15M |
| Share buybacks (net) | -$10M | -$2M | — | — | — | — | — | — | — | — |
| Free cash flow margin | 26.5% | 11.4% | 23.5% | 25.6% | 16.9% | 25.8% | 17.3% | 9.2% | 24.1% | 20.5% |
| Dividends per share | — | — | — | — | — | — | $0.99 | $1.04 | $1.07 | $1.17 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IRMD.
Open IRMD in InvestinglyQuestions
What was Iradimed's revenue in 2025?
$84M in fiscal 2025, from its 10-K filing.
How much free cash flow does Iradimed generate?
$17M in fiscal 2025 (operating cash flow minus capital spending).
From Iradimed's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.